Clinical trials: Oncology
Multiple Myeloma
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI).
- Trial name
- BMT-02 (NCT02043860)
- Testing
- Total Marrow Irradiation, Autologous Transplant, Melphalan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago
Breast Cancer
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants…
- Trial name
- IPATunity130 (NCT03337724)
- Testing
- Ipatasertib, Paclitaxel
- Where
- 176 sites in United States, Argentina and 28 more
- Volunteers
- 579 people
- Sponsor
- Hoffmann-La Roche
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect…
- Trial name
- NCT00836888
- Testing
- ONO-4538
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Glioblastoma, Glioma
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points that are in question and…
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- NCT00723827
- Testing
- Temozolomide, Radiotherapy
- Volunteers
- 682 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.
- Trial name
- EXTAX (NCT03887442)
- Testing
- Paclitaxel, Cetuximab + Paclitaxel
- Volunteers
- 17 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Recurrent Glioblastoma
Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.
- Trial name
- ERGO2 (NCT01754350)
- Testing
- calorie-restricted ketogenic diet and transient fasting, standard nutrition
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
- Trial name
- NCT00258960
- Testing
- Liposomal Doxorubicin, Cyclophosphamide, Trastuzumab
- Where
- 12 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Spanish Breast Cancer Research Group
Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma.
- Conditions
- Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
- Trial name
- NCT04676360
- Testing
- Belantamab Mafodotin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jacob Soumerai, MD
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Malignant Neoplasm, Fatigue
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body.
- Trial name
- NCT02940223
- Testing
- Ethyl Icosapentate, Exercise Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
The specific aim of this study is to determine whether Lovastatin ™ significantly improves visual spatial learning and/or sustained attention in children with NF1.
- Trial name
- STARS (NCT00853580)
- Testing
- Lovastatin ™
- Where
- 12 sites in United States, Australia
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Thoracic Neoplasm
Metformin Pharmacology in Human Cancers: A Proof of Principle Study
This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma concentrations of metformin.
- Trial name
- NCT03477162
- Testing
- Metformin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Breast Cancer, Thyroid Dysfunction
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US.
- Trial name
- B-TREUH (NCT03787303)
- Testing
- Triiodothyronine (T3)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Aultman Health Foundation
Pharmacokinetics, Cancer
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of MK-7252 in healthy adults. Participants receive ascending doses of MK-7252 over five treatment periods.
- Trial name
- NCT03326986
- Testing
- MK-7252
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line…
- Trial name
- JACOB (NCT01774786)
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 172 sites in United States, Australia and 30 more
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
- Trial name
- NCT00443261
- Testing
- Azacitidine, Cisplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Kansas Medical Center
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Other Benign Neoplasm of Skin, Unspecified
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged skin.
- Trial name
- NCT00601640
- Testing
- Diclofenac Na gel, Eflornithine HCL ointment
- Where
- 3 sites in United States
- Volunteers
- 184 people
- Sponsor
- University of Arizona
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.